Curis Propels Two Proprietary Drugs Forward In Plan To Retain Value
Cancer drug developer Curis held its first R&D day Oct. 3, a sign its early pipeline is maturing. The company
outlined development plans for two proprietary drugs, an IAP inhibitor and a PI3K/HDAC inhibitor, both in early
clinical development. As for partnering those assets, CEO Passeri said the company is looking to retain more
value for them than it did for Erivedge.